Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes

Abstract

Patients with LMS with homologous recombination pathway gene alterations have poor clinical outcomes, particularly those with non-<i>BRCA</i> gene alterations. HRD score calculated from a targeted exome panel did not discern disparate clinical outcomes.